Director Olivier Roger Jarry filed a Form 4 with the SEC on October 30, 2026, disclosing the grant of stock options to purchase 300,000 shares of OS Therapies Inc common stock on October 22, 2026.

Key Highlights

  • Option grant date: October 22, 2026, with an exercise price of $1.25 per share.
  • Shares covered: 300,000 options to purchase OS Therapies Inc common stock.
  • Vesting schedule: 12 equal monthly installments beginning on the monthly anniversary of the grant date, contingent on continued service as a director.
  • Expiration date: October 22, 2036, according to the filing.
  • Price paid: $0 for the derivative security at grant.
  • Post-transaction holdings: 300,000 derivative securities beneficially owned directly following the reported transaction.

Director Jarry's Stock Option Grant Details at OS Therapies

According to the Form 4 filed on October 30, 2026, Olivier Roger Jarry, identified as a director of OS Therapies Inc (NASDAQ:OSTX), received a grant of stock options on October 22, 2026. The options carry an exercise price of $1.25 per share and cover 300,000 shares of the issuer's common stock. The filing reports the transaction code as "A," indicating an acquisition of derivative securities.

The filing's explanation of responses states: "On October 22, 2026, the reporting person was granted options to purchase 300,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan." The options are reported as directly owned and vest in 12 equal installments on each monthly anniversary of the grant date, provided that Jarry is serving as a director on each applicable vesting date.

Following the reported transaction, the filing discloses that Jarry beneficially owns 300,000 derivative securities directly. The options expire on October 22, 2036. No non-derivative securities transactions were reported in Table I of the filing. The form was signed by Olivier Jarry on October 30, 2026.

What Was Disclosed

OS Therapies Inc director Olivier Roger Jarry disclosed a grant of 300,000 stock options at an exercise price of $1.25, vesting over 12 monthly installments, with an expiration date of October 22, 2036, under the company's amended and restated 2023 incentive compensation plan.